All relevant data are within the paper.

Introduction {#sec004}
============

Phlebotomine sand flies (Diptera: Psychodidae) are the vectors of Leishmaniases, a group of complex parasitic vector-borne diseases that comprise diverse clinical manifestations in humans, ranging from self-healing cutaneous leishmaniasis to life-threating visceral diseases. Leishmaniases are diseases of great public health concern with an estimated incidence of 0.9--1.6 million new cases each year around the world \[[@pntd.0006769.ref001]\]. The causative agents are several species of the genus *Leishmania* spp. (Kinetoplastida: Trypanosomatidae) which are transmitted to the vertebrate host through the bite of infected sand flies \[[@pntd.0006769.ref002]\].

Despite their importance as disease vectors, sand fly genetics and molecular studies are limited when compared to other insects \[[@pntd.0006769.ref003]\]. One of the main drawbacks is the lack of genome sequence information for most of the sand fly species. To date, only two genome sequencing projects are publicly available; one from the New World species *Lutzomyia longipalpis* and another from the Old World species *Phlebotomus papatasi* \[[@pntd.0006769.ref004]\]. Several sand fly transcriptomes are available \[[@pntd.0006769.ref005]\], mainly focused on salivary glands \[[@pntd.0006769.ref006]--[@pntd.0006769.ref010]\], sand fly-*Leishmania* interactions \[[@pntd.0006769.ref011], [@pntd.0006769.ref012]\] or specific tissues such as the sex pheromone gland \[[@pntd.0006769.ref013]\]. Functional genomic studies have emerged as a potent tool to unravel the molecular mechanisms of the vector-parasite interface. Gene silencing by RNA interference (RNAi) has been widely applied in entomology for the last two decades \[[@pntd.0006769.ref014]\]. Most recently, RNAi has also been incorporated to sand fly studies to address several questions \[[@pntd.0006769.ref015]--[@pntd.0006769.ref017]\]. However, no attempts of gene editing in sand flies have been reported in the literature.

CRISPR, the acronym for "Clustered Regularly Interspaced Short Palindromic Repeats", along with the CRISPR associated proteins (Cas) are part of the adaptive immune system in bacteria and archaea against viral infections \[[@pntd.0006769.ref018]\]. Recently, the CRISPR/Cas system has been adapted for genome engineering and it has rapidly emerged as an effective tool for gene editing in many organisms. Cas9 acts as an RNA-guided endonuclease that specifically recognizes and cleaves the target DNA by base-paring between single guide RNA (sgRNA) and the target sequence (protospacer), creating a double strand break (DSB) \[[@pntd.0006769.ref019]\]. The DSBs are mostly repaired by error-prone non-homologous end joining (NHEJ) that cause gene disruption by introducing insertions or deletions, or by homology-directed repair (HDR), in which genes are replaced by recombination and a homologous sequence is required \[[@pntd.0006769.ref020]\].

In the entomology field, the CRISPR/Cas9 system has triggered a revolution in the study of diverse arthropods including the fruit fly *Drosophila melanogaster* \[[@pntd.0006769.ref021]\], the silkworm *Bombyx mori* (Lepidoptera) \[[@pntd.0006769.ref022]\], the red flour beetle *Tribolium castaneum* (Coleoptera) \[[@pntd.0006769.ref023]\] and the European honey bee *Apis mellifera* (Hymenoptera) \[[@pntd.0006769.ref024]\] among others \[[@pntd.0006769.ref025]\]. In the vector biology field, the CRISPR/Cas9 system has enabled studies of both Culicinae and Anophelinae mosquitoes relevant to mosquito biology, insecticide resistance and vector control strategies \[[@pntd.0006769.ref026]--[@pntd.0006769.ref036]\].

In the present paper, we describe the methodology for sand fly embryo microinjection and we discuss several essential factors for the incorporation of CRISPR/Cas9 methodology in the sand fly field. We believe that this powerful gene-editing tool will be useful for the sand fly community to better understand the sand fly biology and will help to decipher vector-parasite-host interactions.

Methods {#sec005}
=======

Ethics statement {#sec006}
----------------

Public Health Service Animal Welfare Assurance \#A4149-01 guidelines were followed according to the National Institute of Allergy and Infectious Diseases (NIAID) and the National Institutes of Health (NIH) Animal Office of Animal Care and Use (OACU). Sand fly maintenance was carried out according to the NIAID-NIH animal study protocol (ASP) approved by the NIH Office of Animal Care and Use Committee (OACUC), with approval ID ASP-LMVR4E.

Selection of target gene {#sec007}
------------------------

Sand fly genetic information is scarce when compared to the fruit fly or mosquito genomic resources. There are two sand fly genomes annotated so far: *Lu*. *longipalpis* (Lutz & Neiva, 1912) Jacobina strain, vector of visceral leishmaniasis in the New World and *Phlebotomus papatasi* Israeli strain, vector of cutaneous leishmaniasis in the Old World \[[@pntd.0006769.ref004]\]. We encourage comparing the target gene sequence from the sand fly colony with the annotated gene in the databases (VectorBase or NCBI) before designing the sgRNA, as single nucleotide polymorphisms may be enough for changing the protospacer adjacent motif (PAM) or sgRNA recognition by Cas9. The steps followed for selection of the target gene are listed below:

1.  Primer design of the target gene was based on annotated databases.

2.  Genomic DNA (gDNA) from whole sand flies or specific tissues of interest was isolated by DNeasy Blood and Tissue Kit (QIAGEN) following manufacturer's instructions.

3.  PCR was performed with specific primers (0.2 μM) to amplify the gene of interest from 200 ng of gDNA with Platinum High Fidelity Taq polymerase (Invitrogene). PCR conditions were as follows: 2 min at 94 °C, 35 cycles of 15 sec, 94 °C, 30 sec at the annealing temperature specific for the primers used and an extension step of 68 °C for 1 min/kb.

4.  PCR product was purified (SpinPrep PCR Clean-up Kit, Millipore) and an aliquot of 20--40 ng/μl was sent for sequencing.

5.  Electropherograms were manually inspected and aligned with the annotated sequences using SeqMan Pro (DNASTAR, Lasergene 12).

sgRNA design {#sec008}
------------

Once the target DNA sequence region was verified, specific sgRNA were designed using CHOPCHOP v2 software \[[@pntd.0006769.ref037]\] (<http://chopchop.cbu.uib.no/index.php#>) which contains the *Lu*. *longipalpis* Jacobina strain LlonJ1 genome \[[@pntd.0006769.ref004]\]. Default parameters for designing sgRNA with CHOPCHOP software v2 were set: off-target with up to 3 mismatches in protospacer \[[@pntd.0006769.ref038]\], with an efficiency score based on Xu *et al*. \[[@pntd.0006769.ref039]\] and self-complementary according to Thyme *et al*. \[[@pntd.0006769.ref040]\]. The chosen sgRNA sequences need to be incorporated into forward primers along with the T7-promoter region and a sequence complementary to a common reverse primer (Scaffold-R, [Table 1](#pntd.0006769.t001){ref-type="table"}), part that would bind the Cas9 protein.

10.1371/journal.pntd.0006769.t001

###### sgRNA targeting *LuloYLW* gene.

![](pntd.0006769.t001){#pntd.0006769.t001g}

  sgRNA        5'- T7-promoter [Gene-specific (20mer)]{.ul} Scaffold-F (CRISPR) -3'               Genomic location    PAM   Strand   GC (%)   Self-complementarity   Off-targets   Efficiency
  ------------ ---------------------------------------------------------------------------------- ------------------- ----- -------- -------- ---------------------- ------------- ------------
  LuloYLW_1    **GAAATTAATACGACTCACTATAGG**[ATATGGGCAGGGATTCCTAG]{.ul}GTTTTAGAGCTAGAAATAGC        Scaffold614:35631   TGG   \-       52       0                      0             0.57
  LuloYLW_2    **GAAATTAATACGACTCACTATAGG**[GACATTGAGAGCATATGGGC]{.ul}GTTTTAGAGCTAGAAATAGC        Scaffold614:35643   AGG   \-       52       0                      0             0.62
  LuloYLW_3    **GAAATTAATACGACTCACTATAGG**[TCATATTGGTGTCCTCAGGT]{.ul}GTTTTAGAGCTAGAAATAGC        Scaffold614:35707   CGG   \-       52       0                      0             0.49
  LuloYLW_4    **GAAATTAATACGACTCACTATAGG**[GCGCTACGTTCTCCGACCTG]{.ul}GTTTTAGAGCTAGAAATAGC        Scaffold614:35695   AGG   \+       65       0                      0             0.57
  LuloYLW_5    **GAAATTAATACGACTCACTATAGG**[CTGATGTCTGCGGTAGGCTT]{.ul}GTTTTAGAGCTAGAAATAGC        Scaffold614:35574   TGG   \+       57       0                      0             0.49
  LuloYLW_6    **GAAATTAATACGACTCACTATAGG**[CGCATCAAGGCTGATGTCTG]{.ul}GTTTTAGAGCTAGAAATAGC        Scaffold614:35564   CGG   \+       61       1                      0             0.46
  Scaffold-R   AAAAGCACCGACTCGGTGCCACTTTTTCAAGTTGATAACGGACTAGCCTTATTTTAACTTGCTATTTCTAGCTCTAAAAC                                                                                    

sgRNA production {#sec009}
----------------

DNA templates for each sgRNA were produced by PCR with specific primers followed by *in vitro* transcription. The steps are listed below:

1.  PCR amplification of overlapping primers was performed with Platinum PCR SuperMix following manufacturer's instructions (Invitrogen).

2.  Purification of DNA was carried out with SpinPrep PCR Clean-up Kit (Millipore) and used as template for transcription reaction (500 ng of starting material per reaction) with the MEGAscript T7 Transcription Kit (Ambion).

3.  Transcription reactions were run for 20 h followed by DNase*I* treatment (20 min at 37 °C).

4.  RNA concentration was determined by Nanodrop ND-1000 spectrophotometer.

5.  sgRNAs were resuspended with DEPC-H~2~0 and adjusted to 2500 ng/μl and stored at -80 °C in 10 μl single use aliquots.

*Streptococcus pyogenes* Cas9 production {#sec010}
----------------------------------------

For Cas9 mRNA production, pRGEN-Cas9-CMV plasmid (PNA Bio) was linearized by *Xho*I over-night digestion at 37 °C and used as a template for transcription reaction following mMessage mMachine T7 Ultra kit instructions (Ambion).

Cas9 protein expression and purification was performed as described by Zuris *et al*. \[[@pntd.0006769.ref041]\] with several modifications:

1.  *Escherichia coli* BL21 STAR (D3)-competent cells (Invitrogen) were transformed with pET-NLS-Cas9-6xHis plasmid (Addgene 62934).

2.  Transformed bacteria were grown in 100 ml of Luria-Bertani (LB) broth in the presence of 100 μg/ml ampicillin overnight at 250 rpm, 37 °C.

3.  The following day, cells were 1:100 diluted in fresh LB broth with antibiotic (1-liter culture) and incubated until culture reached OD~600~ of 0.6--0.7.

4.  Protein expression was induced with 1 mM isopropyl β-D-1- thiogalactopyranoside for 16 h at 22 °C.

5.  Bacterial cells were collected by centrifugation at 6,000 rpm for 15 min at 20 °C. Cells were resuspended in 10 mM Tris-HCl, 500 mM NaCl, pH 8.0 and lysed by sonication (3 pulses of 30 sec each at 50W, kept on ice for 30 sec between pulses).

6.  Cell lysate was cleared by 2 step-centrifugation (first centrifugation at 10,000 rpm for 10 min and a ultracentrifugation of the cloudy supernatant at 40,000 rpm for 30 min at 4 °C, Beckman Coulter).

7.  Recombinant Cas9 protein was purified from the soluble cell lysate by affinity and cation exchange chromatography: For affinity chromatography, cell lysate was passed through a 0.1 M Nickel-charged 5 ml HiTrap Chelating HP (GE Healthcare Life Science, Piscataway, NJ) and the protein was eluted by creating a gradient of Imidazole (0--500 mM) that released the binding of the Nickel and the His-tag.Chromatography fractions were checked on a 4--12% NuPage gel (Life Technologies) and proteins were visualized by Coomassie stain.Fractions that contain the recombinant Cas9 were combined and NaCl was removed by dialysis with 25 mM 2-(N-Morpholino) ethanesulfonic acid (MES), pH 6.0 at 4 °C overnight using dialysis cassettes (Thermo Scientific, MWCO 10 kDa).The protein was further purified by cation exchange chromatography on a MonoS 5/50 GL column (GE Healthcare Life Science, Piscataway, NJ). The protein was eluted by increasing ion strength (0--1000 mM NaCl).Chromatography fractions were visualized on a gel and proper fractions were combined.Protein was dialyzed with 25 mM Tris-HCl, 150 mM NaCl, pH 7.3 overnight using dialysis cassettes (Thermo Scientific, MWCO 10 kDa).The concentration was determined based on the assumption that 1 mg ml^-1^ has an absorbance at 280 nm of 0.76, according to the molecular extinction coefficient (120,700 M^-1^ cm^-1^).

All protein purification experiments were carried out using an AKTA purifier system (GE Healthcare Life Science, Piscataway, NJ). Home-made Cas9 protein activity was tested by comparison with commercial recombinant Cas9 protein, that was purchased from PNABio (CP02). If home-made Cas9 protein expressed in bacteria is going to be included in the injection mix, endotoxin levels should be monitored to ensure no bacteria lipopolysaccharide is microinjected into the embryo.

*In vitro* cleavage assay {#sec011}
-------------------------

To test the ability of each sgRNA to cut the target DNA *in vitro*, we checked the integrity of the target DNA region after incubation with the sgRNA in the presence of Cas9 protein in an *in vitro* cleavage assay.

1.  The target gene was amplified from gDNA or cDNA (assuming target region was within an exon) from *Lu*. *longipalpis* using Platinum DNA polymerase (Invitrogen) with 0.2 μM of specific primers. The PCR product was purified (SpinPrep PCR Clean-up Kit, Millipore) and used as template for the *in vitro* cleavage assay.

2.  Cas9 protein (400 ng; 3.8 μM) was pre-incubated with each individual sgRNA (30 ng; 3.2 μM) for 10 min at 37 °C to ensure proper loading of the sgRNA.

3.  Target DNA (200 ng) was mixed to pre-loaded Cas9 protein and reactions were incubated at 37 °C in the presence of 1X Bovine Serum Albumin and 1X NEB3 buffer (New England Biolabs) in a total volume of 20 μl.

4.  After 1 h and 15 min incubation period, Cas9 protein was inactivated at 65 °C for 10 min.

5.  As controls, template DNA were incubated with individual sgRNA in the absence of Cas9 protein. In addition, target DNA with and without Cas9 protein were included.

6.  Samples and controls were run in a 0.5 μg/ml ethidium bromide 2.2% agarose gel and the loading buffer (Thermo Fisher Scientific) was supplemented with 0.1% SDS.

7.  Tris-acetate-EDTA (KD Medical) was used as a running buffer for DNA electrophoresis and bands were visualized and scanned under UV light.

Injection mix {#sec012}
-------------

Initially, injection mixes consisted of 600 ng/μl Cas9 mRNA and a mixture of 100 ng/μl of each sgRNA in nuclease free water. Each injection mix was freshly prepared on the day of the injection, centrifuged at 13,000 rpm at 4 °C and kept on ice during microinjections.

As an alternative to mRNA, Cas9 protein can be included in the injection mix. A final concentration of 330 ng/μl Cas9 with 100 ng/μl of each sgRNA would be in the equimolar range. Tubes containing Cas9 protein should be independently loaded with the individual sgRNAs for 10 min at 37 °C to avoid Cas9 binding sgRNA with different affinities potentially resulting in different degrees of sgRNA loading.

Pulling needles {#sec013}
---------------

Borosilicate glass capillaries needles (\#1B100-4, Kwik-Fil) were laser-pulled using a Sutter P-2000 micropipette puller (Novato, CA, USA, [Fig 1A](#pntd.0006769.g001){ref-type="fig"}) and parameters were set as follows: Heat = 270, FIL = 3, VEL = 25, DEL = 250, PUL = 140. Needles were beveled to an angle of 20° (Sutter BV-10 Microelectrode Beveller, 104D fine abrasive plate, [Fig 1B and 1C](#pntd.0006769.g001){ref-type="fig"}). All needles were inspected under a microscope ([Fig 1D](#pntd.0006769.g001){ref-type="fig"}) and the ones with a bore greater than 1 μm were discarded to avoid embryo damage.

![Needle preparation.\
**(A)** Needles were pulled using a Sutter P-2000 micropipette puller. **(B) (C)** Pulled needles were beveled to an angle of 20° using a Sutter BV-10 Microelectrode Beveller, 104D fine abrasive plate. **(D)** Needles were inspected under a microscope to ensure the bore is not greater than 1 μm. NOTE: If there is no availability of a needle beveller, needles can be opened by breaking the bore towards a glass slide under the microscope (always verify the opening is smaller than 1 μm).](pntd.0006769.g001){#pntd.0006769.g001}

Sand fly embryo microinjection {#sec014}
------------------------------

*Lutzomyia longipalpis* Jacobina strain was reared following standard conditions at the Laboratory of Malaria and Vector Research (LMVR), National Institutes of Health (NIH). The embryo microinjection protocols as described by Aryan *et al*. \[[@pntd.0006769.ref042]\] were followed and adapted to sand fly work.

1.  *Lu*. *longipalpis* blood-fed 4 to 6-day-old females were held for 5--7 days in adult cages to avoid non-synchronized egg laying ([Fig 2A](#pntd.0006769.g002){ref-type="fig"}).

2.  On the day of microinjection, gravid sand flies were transferred to manually prepared card box cages with humid hardened filter paper on the bottom (grade 50, Whatman, [Fig 2B and 2C](#pntd.0006769.g002){ref-type="fig"}).

3.  Sand flies were allowed to lay eggs in the dark for 1 h at 27 °C and freshly laid, non-melanized eggs were collected with a fine brush ([Fig 2D](#pntd.0006769.g002){ref-type="fig"}).

4.  Embryos were aligned towards a humid filter paper (grade 50, Whatman) and oriented in the same anterior-posterior direction to allow injection of material into the posterior pole. Aligned embryos were desiccated for a few seconds by drying out the filter paper before being transferred to a coverslip with double-sided adhesive tape along the edge. Embryos were immediately covered with halocarbon oil 27 (Sigma, St. Louise, MO) to prevent over-desiccation ([Fig 2E and 2F](#pntd.0006769.g002){ref-type="fig"}).

5.  The injection mix was loaded into the needle and 1 h 30 min to 3 h old *Lu*. *longipalpis* embryos were microinjected in the posterior pole using a Femtoject 4i microinjector (Eppendorf) and a Leica micromanipulator ([Fig 2G and 2H](#pntd.0006769.g002){ref-type="fig"}).

6.  After injection, halocarbon oil was removed with distilled water and injected embryos were transferred with the help of fine tweezers (Dumont \#5 Inox 11 cm) or a fine brush to a small plastic beaker with humid filter paper. Embryos were kept at 27 °C for 2 days before being transferred to plaster of Paris larval pots. (\[[@pntd.0006769.ref043]\], <https://www.vectorbase.org/content/cd-sand-fly-fellas-sand-fly-rearing-guide>).

![Layout of sand fly embryo microinjection.\
**(A)** Blood fed females were maintained in adult cages for 5--7 days. **(B, C)** Gravid sand fly females were transferred to paper cups with a humid filter paper on the bottom to promote oviposition. Sand flies were allowed to lay eggs in the dark for 1 h and recently laid eggs **(D)** were collected. **(E)** Alignment of embryos was performed on humid filter paper under a dissecting microscope. **(F)** Embryos were transferred from the filter paper to a cover slip with double-sided tape and covered with halocarbon oil to prevent desiccation. **(G)** Cover slip containing the embryos was placed on the microscope stage and **(H)** the borosilicate needle backfilled with the injection mixture was adjusted towards the posterior end of the embryo to start microinjections.](pntd.0006769.g002){#pntd.0006769.g002}

Results and discussion {#sec015}
======================

Although gene editing has become a widespread practice in all fields of science, including medical entomology \[[@pntd.0006769.ref044]--[@pntd.0006769.ref046]\], genome editing based mutagenesis has not yet been documented in the sand fly model. In this article, we describe a detailed protocol to perform sand fly embryo microinjection, an essential step for CRISPR/Cas9 gene editing experiments.

The *Yellow* gene (LuloYLW), responsible for pigmentation of the sand fly body, was chosen as a target gene for the sgRNA production and embryo microinjection protocol. The Drosophila *yellow* ortholog in *Lu*. *longipalpis* was identified through tblastx analysis as LLOJ007802 (E-value: 4e-168), located in scaffold614: 30,092--37,432 in the forward strand. According to the VectorBase (VB) database, its transcript consists of 4 exons ([Fig 3A](#pntd.0006769.g003){ref-type="fig"}) and codify a protein of 512 amino acids. To confirm these results, LLOJ007802 was sequenced using gDNA of 4 individual sand flies (2 females and 2 males). Although some single nucleotide polymorphisms were found between the LLOJ007802 transcript annotated sequence and our *Lu*. *longipalpis* sand flies, the overall similarity was maintained. However, we found that the LLOJ007802 gene consists of only 3 exons and not 4, as annotated in the VB database. The second exon designated in the VB database (5'-GAATTCCCGCCACATTGACGTACATTGATCTCGACAAGACACCATCAG-3') is a repetition of the beginning of the third exon. Alignment with amino acid sequences from other related yellow proteins confirmed the absence of the exon 2 ([Fig 3B](#pntd.0006769.g003){ref-type="fig"}).

![Detail on *Lutzomyia longipalpis* yellow gene intronic-exonic information and protein alignment.\
**(A)** Intron-exon organization of yellow gene from *Lu*. *longipalpis* E1, E2, E3 and E4 indicates the different hypothetical exons according to the VectorBase database LLOJ007802. **(B)** Multiple sequence alignment of yellow protein from sand flies *Lu*. *longipalpis* (Lulo) and *P*. *papatasi* (Pap), and other related species: *Drosophila melanogaster* (Dro), *Ae*. *aegypti* (Aed), *An*. *gambiae* (Ang) and *Culex quinquefasciatus* (Cuq). Accession numbers are indicated in the sequence name. Sequence correspondent to hypothetical exon 2 from LLOJ007802 is higlighted within a dotted box. Sequences without signal peptide were aligned with ClustalW and refined using Boxshade server, and the percent identity or similarity for shading was set at 80%. Black background shading represents identical amino acids, grey shading designates similar amino acids while white shading indicates no similarity.](pntd.0006769.g003){#pntd.0006769.g003}

The LuloYLW gene was inspected in search of PAM sequences for Cas9 endonuclease (NGG) with the help of CHOPCHOP software. Six sgRNA of 20 nucleotides length were designed next to PAM sequences in the exon 3, where the major royal jelly protein domain (pfam03022) is located ([Table 1](#pntd.0006769.t001){ref-type="table"}). Three sgRNA in each DNA strand were chosen and both self-complementary and off-targets were avoided. To generate the sgRNA, overlapping forward specific and a complementary common reverse primer were amplified. Purified PCR products served as templates for transcription to obtain the sgRNA. Once purified, sgRNA were kept individually in 2500 ng/μl aliquots at -80 °C until used. To validate the sgRNA, we tested the ability of each sgRNA to cut the target DNA *in vitro*. The target DNA region (exon 3) was amplified from cDNA of 10 female *Lu*. *longipalpis* using Platinum DNA polymerase (Invitrogen) with 0.2 μM of specific primers (LuloYLW-E3-F: 5'-GAATTCCCGCCACATTGACG-3' and LuloYLW-E3-R: 5'-CCAATTCGTCGGACATATAAGC-3'). Visualization of the integrity of the target DNA showed that all 6 sgRNA tested were able to drive Cas9 protein to cleave the target DNA resulting in fragments that matched the expected size, according to each cleavage site ([Fig 4](#pntd.0006769.g004){ref-type="fig"}).

![All six sgRNA produce Cas9-driven cleavage *in vitro*.\
200 ng of the PCR product of the LuloYLW gene exon 3 were incubated with each individual sgRNA (3.2 μM) in the absence (lanes 1--6) or presence of 3.8 μM Cas9 protein (lanes 7--12). DNA bands size corresponds to the expected size according to each cleavage site (sgRNA1 = 218 bp, 154 bp; sgRNA2 = 230 bp, 142 bp; sgRNA3 = 294 bp, 78 bp; sgRNA4 = 279 bp, 93; sgRNA5 = 158 bp, 214 bp and sgRNA6 = 148 bp, 224 bp). As negative controls, 200 ng of PCR product alone (lane 13) or in combination with Cas9 protein (lane 14) were included. All samples were run on 2.2% agarose gels and visualized under UV light.](pntd.0006769.g004){#pntd.0006769.g004}

Cas9 recombinant protein was successfully expressed and purified in our laboratory starting from the initial cloning of the commercial plasmid Addgene 62934 ([Fig 5](#pntd.0006769.g005){ref-type="fig"}). A yield of 0.7 mg of purified protein per liter of culture was achieved with this protocol. The recombinant Cas9 protein run on a gel at the expected molecular weight and its endonuclease activity was demonstrated as shown in a side by side comparison in an *in vitro* cleavage assay with the *in house* recombinant protein and a commercial one (PNABio) using the same sgRNAs ([Fig 5](#pntd.0006769.g005){ref-type="fig"}).

![Purification of Cas9 recombinant protein.\
**(A)** Purification of Cas9 by affinity chromatography using a Nickel-charged HiTrap Chelating HP. Gradient of Imidazole is indicated by the green line. **(B)** Coomassie-stained gel electrophoresis of peaks 1 and 2 after affinity chromatography (26 μl of each fraction) shows that peak 2 corresponds to Cas9. M: SeeBlue Plus2 Pre-Stained Protein Standard (Life Technologies). **(C)** Purification of Cas9 by cation-exchange chromatography using a MonoS 5/50 GL column. Gradient of NaCl is indicated by the green line. **(D)** Coomassie-stained gel electrophoresis of fractions correspondent to different peaks after cation-exchange chromatography (26 μl of each fraction, peaks 1--4: lanes 1--4). All peaks showed a band of the correct Cas9 molecular weight. Only the majoritarian peak (\#2) was collected. Lane 5 corresponds to purified Cas9 after dialysis. M: SeeBlue Plus2 Pre-Stained Protein Standard (Life Technologies). **(E)** Purification of recombinant Cas9 produced in our laboratory showed endonuclease activity comparable to a commercial Cas9 (PNABio). 200 ng of PCR product of target gene was incubated with each individual sgRNA (lanes 1--12; 3.2 μM) in the presence of 3.8 μM Cas9 protein either purchased from PNABio (upper gel) or obtained in our laboratory (lower gel). As negative controls, 200 ng of PCR product alone (lane 13) or in combination with Cas9 protein (lane 14) were included. All samples were run on 2.2% agarose gels and visualized under UV light.](pntd.0006769.g005){#pntd.0006769.g005}

Three sets of microinjections were carried out. A total of 775 embryos were injected with the mixture of sgRNAs and Cas9 mRNA (84, 269 and 422 for each set of injection). After microinjection, halocarbon oil was washed off and injected embryos were deposited into a beaker with humid filter paper on the bottom. Two days after microinjection, embryos were transferred to a larva pot with humid plaster of Paris base. Ten, thirty-eight and sixty embryos respectively, hatched resulting in hatching rates of 11.90%, 14.13% and 14.22%, values slightly lower to other non-model insects, such as mosquitoes \[[@pntd.0006769.ref047], [@pntd.0006769.ref048]\]. In this specific setting, hatching rates of non-injected wild type embryos were 64.7%. From the third set of microinjections, larvae were followed. These 60 larvae were separated at prepupae stage in individual polypropylene vials (height 5.4 cm, diameter 2.2 cm) with plaster of Paris on the bottom ([Fig 6A](#pntd.0006769.g006){ref-type="fig"}) to maintain proper humidity. 42 G~0~ larvae survived and were sexed (20 males and 22 female pupae). It is important to note that germ-line mutagenesis experiments require virgin female adults, which can be easily obtained by sexing pupae according to differences in the last pupal segment as shown in [Fig 6B](#pntd.0006769.g006){ref-type="fig"}.

![Details of G~0~ sand fly individuals and pupae sexing.\
**(A)** G~0~ pre-pupae were separated into individual tubes with humid plaster of Paris on the bottom to allow them to pupate. Inset image shows a magnification of a sand fly pupa in the tube. **(B)** Sand fly pupae were sexed according to the shape of the last pupal segment, which in males is larger and more rounded than in female pupa (differences indicated by red arrows).](pntd.0006769.g006){#pntd.0006769.g006}

Nuclease activity of *Streptococcus pyogenes* Cas9 (SpCas9) can be triggered when there is imperfect complementarity between the sgRNA and a genomic site leading to genomic off-target mutagenesis. Lately, engineered Cas9 with improved specificity, such as eSpCas9, SpCas9-HF or HypaCas9, have arisen providing a more robust on-target cleavage \[[@pntd.0006769.ref049]--[@pntd.0006769.ref051]\]. Although we used SpCas9 in our experiments, it would be beneficial for future studies to substitute the SpCas9 with any of their improved versions.

Having a successful microinjection for germ line transformation depends mainly on two factors. The first factor is the melanization process of the egg. Upon oviposition, sand fly embryos, like other dipterans, start to melanize and harden. Injection of freshly laid embryos will result excessive damage resulting in the death of the embryos since the chorion is not sufficiently hardened. On the other hand, when they are too melanized, the needle will be unable to penetrate the hardened chorion. In our observations, the proper time for injection of sand flies regarding melanization was between 1 h 30 min and 3 h after egg laying. In that period of time *Lu*. *longipalpis* embryos have acquired the appropriate degree of melanization for microinjections that simultaneously involve hardening of the chorion. [Fig 7](#pntd.0006769.g007){ref-type="fig"} illustrates the melanization process over time in *Aedes aegypti* and *Lu*. *longipalpis*. The time window is greater than with mosquitoes which need to be injected within minutes after aligning \[[@pntd.0006769.ref042], [@pntd.0006769.ref052], [@pntd.0006769.ref053]\].

![Melanization of embryos over time.\
Preferred melanization stages for injection are indicated with dotted brackets. **(A)** *Aedes aegypti* embryos are best injected between 45 min and 1 h 30 min, when they are getting darker, so their chorion is hardened enough to protect the embryo from bursting but not too hard that they would break the needle. Scale bar = 500 μm. *Aedes aegypti* (Liverpool strain, LMVR, NIH) gravid female mosquitoes were transferred to a 50-ml tube (Falcon, Fisher Scientific) with a humid filter paper on the bottom to promote egg laying. **(B)** *Lutzomyia longipalpis* takes longer to start melanizing. The time frame for optimal *Lu*. *longipalpis* embryo microinjections is between 1 h 30 min and 3 h after oviposition. Scale bar = 250 μm. For visualization of the melanization process, both *Ae*. *aegypti* and *Lu*. *longipalpis* were allowed to lay eggs for five min.](pntd.0006769.g007){#pntd.0006769.g007}

The second factor that determines the success of the germ line gene editing is the localization of the injection mix within the embryo and peculiarities of embryology (ie, location for developing pole cells/ germ cells). The injected material needs to be delivered at pre-blastoderm stage when the polar cells are forming and before cellularization occurs. Information on sand fly embryology is scarce. The few reports describing the embryology of *P*. *papatasi* indicate that pole cells formation occurs in the posterior end of the egg, just beneath the vitelline membrane by 36 h after oviposition \[[@pntd.0006769.ref054]\]. Pole cells formation in sand flies takes place much later than in *D*. *melanogaster* or mosquitoes which occurs around 1 h 30 min after egg laying \[[@pntd.0006769.ref042], [@pntd.0006769.ref055]\]. This is concordant with the embryonic development time (from oviposition until hatching) in the different insect species. It takes 1 day for fruit fly embryos to hatch \[[@pntd.0006769.ref055]\], 2--3 days for mosquito embryos \[[@pntd.0006769.ref056]\] and more than a week for sand fly embryos \[[@pntd.0006769.ref043]\]. Depending on the sand fly species, development time varies (9 days for *P*. *papatasi* \[[@pntd.0006769.ref054]\], 8 days for *Lu*. *longipalpis* Jacobina strain \[[@pntd.0006769.ref057]\]). Therefore, the time window for microinjection to target the polar cells in sand flies is substantially wider. Hence, what determines the injection time window is the hardness of the cuticle as discussed above.

The CRISPR/Cas9 system uses sgRNA to specifically cleave the DNA resulting in double-stranded break (DSB) in the genome \[[@pntd.0006769.ref021]\]. DSB are repaired by classical non-homologous end joining (C-NHEJ) or homologous directed repair (HDR). Although both repair mechanisms are competitive, C-NHEJ is strongly preferred over HDR in *Ae*. *aegypti* \[[@pntd.0006769.ref030]\]. Other repair mechanisms such as alternative non-homologous end joining (A-NHEJ) or single-strand annealing (SSA) can also play a role \[[@pntd.0006769.ref058]\]. The NHEJ pathway is an error-prone mechanism that cause gene disruption by introducing insertions or deletions, whereas for HDR, genes are replaced by recombination and a homologous sequence is required. Unravelling the DNA repair mechanisms is essential to understanding gene editing outcomes. A lack of information on DNA repair pathways in sand flies makes it difficult to estimate the potential knock-out or knock-in outcomes. To gain information on DSB mechanisms in sand flies, a bioinformatic search for orthologs involved in NHEJ, HDR or SSA pathways was carried out ([Table 2](#pntd.0006769.t002){ref-type="table"}). Most of the known genes involved in DSB repair in *Anopheles gambiae* or *D*. *melanogaster* were also identified in *Lu*. *longipalpis* indicating that all DSB repair mechanisms are potentially feasible.

10.1371/journal.pntd.0006769.t002

###### Orthologs of DNA break repair genes in *Lutzomyia longipalpis*.

![](pntd.0006769.t002){#pntd.0006769.t002g}

  Gene          C-NHEJ   A-NHEJ   HDR   SSA   *An*. *gambiae*   *D*. *melanogaster*   *Lu*. *longipalpis*   Location                        Strand    Search method                         *e-value*
  ------------- -------- -------- ----- ----- ----------------- --------------------- --------------------- ------------------------------- --------- ------------------------------------- -----------
  Ku70          x                             AGAP002690        FBgn0011774           LLOJ003544            Scaffold21: 254,199--263,494    Reverse   tblastn to *An*. *gambiae* gene       5.00E-135
  Ku80          x                             AGAP009910        FBgn0041627           LLOJ009466            Scaffold876: 4,739--6,975       Reverse   tblastn to *An*. *gambiae* gene       2.00E-134
  DNA-PKcs      x                             AGAP003967        Absent                LLOJ003970            Scaffold2350: 929--24,122       Forward   tblastn to *An*. *gambiae* gene       0
  Ligase 4      x                             AGAP000623        FBgn0030506           LLOJ008477            Scaffold71: 184,650--188,282    Reverse   tblastn to *An*. *gambiae* gene       4.00E-15
  Artemis       x                             AGAP000597        Not identified        LLOJ009728            Scaffold92: 6,692--12,025       Reverse   tblastn to *An*. *gambiae* gene       8.00E-42
  APLF          x                             AGAP004516        FBgn0026737           Not identified                                                  tblastn to *An*. *gambiae* gene       
  PNKP          x                             AGAP012174        FBgn0037578           LLOJ000482            Scaffold1077: 23,640--25,668    Reverse   tblastn to *An*. *gambiae* gene       4.00E-24
  APTX          x                             AGAP004307        FBgn0038704           LLOJ001322            Scaffold126: 92,455--93,613     Forward   tblastn to *An*. *gambiae* gene       6.00E-29
  Parp1                  x                    AGAP003230        FBgn0010247           LLOJ001283            Scaffold125: 56,700--70,597     Reverse   tblastn to *An*. *gambiae* gene       2.00E-60
  Ligase 3               x                    Absent            FBgn0038035           LLOJ008477            Scaffold71: 184,650--188,282    Reverse   tblastn to *D*. *melanogaster* gene   2.00E-43
  Ligase 1               x                    AGAP009222        FBgn0262619           LLOJ008476            Scaffold71: 183,315--187,114    Forward   tblastn to *An*. *gambiae* gene       0
  Xrcc3                  x                    AGAP013180        FBgn0003480           LLOJ005967            Scaffold4: 274,950--281,740     Forward   tblastn to *An*. *gambiae* gene       2.00E-28
  Xrcc1                  x                    AGAP002605        FBgn0026751           LLOJ004541            Scaffold268: 78,732--80,341     Forward   tblastn to *An*. *gambiae* gene       1.00E-47
  ATM                    x                    AGAP009632        FBgn0045035           LLOJ002603            Scaffold17: 281,505--321,286    Reverse   tblastn to *An*. *gambiae* gene       1.00E-170
  Mre11                  x        x           AGAP006797        FBgn0020270           LLOJ006671            Scaffold485: 146,630--151,328   Forward   tblastn to *An*. *gambiae* gene       2.00E-157
  Rad50                  x        x           AGAP003676        FBgn0034728           LLOJ001007            Scaffold118: 147,175--151,533   Forward   tblastn to *An*. *gambiae* gene       0
  Nbs1                   x        x           AGAP003213        FBgn0261530           LLOJ000672            Scaffold1100: 41,240--43,475    Reverse   tblastn to *An*. *gambiae* gene       3.00E-54
  Sae2                   x        x           AGAP008637        FBgn0029113           LLOJ009358            Scaffold86: 50,707--65,797      Forward   tblastn to *An*. *gambiae* gene       0
  Exo1                            x           AGAP004491        FBgn0015553           LLOJ003541            Scaffold21: 238,272--240,297    Forward   tblastn to *An*. *gambiae* gene       7.00E-19
  RPA                             x           AGAP001421        FBgn0010173           LLOJ006328            Scaffold437: 68,232--71,334     Reverse   tblastn to *An*. *gambiae* gene       0
  Sgs1                            x           AGAP002967        FBgn0002906           LLOJ001099            Scaffold12: 322,054--329,185    Forward   tblastn to *An*. *gambiae* gene       0
  Dna2                            x           AGAP004685        FBgn0030170           LLOJ003812            Scaffold227: 12,526--19,819     Reverse   tblastn to *An*. *gambiae* gene       0
  Rad51                           x           AGAP013412        FBgn0003479           LLOJ000926            Scaffold1164: 24,172--26,802    Reverse   tblastn to *An*. *gambiae* gene       2.00E-171
  Rad54                           x           AGAP008748        FBgn0002989           LLOJ000406            Scaffold106: 72,542--75,384     Forward   tblastn to *An*. *gambiae* gene       0
  BRCA2                           x           AGAP007032        FBgn0050169           Not identified                                                                                        
  Polδ                            x           AGAP011731        FBgn0263600           LLOJ000780            Scaffold113: 143,876--150,886   Forward   tblastn to *An*. *gambiae* gene       8.00E-26
  Polθ                            x           AGAP004615        FBgn0264326           Not identified                                                                                        
  Rad1                                  x     AGAP002255        FBgn0026778           LLOJ004989            Scaffold305: 92,142--93,895     Forward   tblastn to *An*. *gambiae* gene       1.00E-37
  Rad10/Ercc1                           x     AGAP004029        FBgn0028434           LLOJ005134            Scaffold320: 65,326--117,135    Forward   tblastn to *An*. *gambiae* gene       1.00E-16
  Msh2                                  x     AGAP010282        FBgn0015546           LLOJ000903            Scaffold1156: 46,215--59,400    Reverse   tblastn to *An*. *gambiae* gene       0
  Slx4                                  x     AGAP007582        FBgn0002909           Not identified                                                                                        

A critical issue for genome engineering in sand flies is the size and the fragility of these insects. Screening of knock-outs requires extraction of gDNA. In mosquitoes, genotyping alive individuals can be performed with gDNA obtained from a single rear leg. In contrast, we found that sand flies are too fragile for this procedure. Excessive manipulation of alive individuals may result in stress and high mortality rates. Instead, genotyping can be performed after an individual has been already crossed, blood-fed and laid eggs using the live sand fly or its recently dead body as a source of DNA material using the Phire Animal Tissue Direct PCR Kit (Thermo Fisher Scientific). However, genotyping can be an issue if the identification of alive heterozygous individuals is needed for out-crossing to create a homozygous line. In this case, extracting gDNA from the pupal exuviae has been a valid option for other organisms \[[@pntd.0006769.ref059]\]. It is important to emphasize the relevance of the proper design of the sgRNA. They should target genomic areas where no single nucleotide polymorphisms (SNPs) are present at inter and intra-individual level. Preliminary work of sequencing the target gene from several specimens is highly recommended before designing the sgRNA.

In this article, we described a protocol for sand fly embryo microinjection and addressed several issues related to microinjection and gene editing with a non-model organism. We believe gene editing in sand flies will provide essential information of great relevance to medicine and veterinary science on the biology of these vectors, and will further a better understanding of vector-parasite interactions.
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